CClinicalTrials.gg
WithdrawnNCT03534388Updated Sep 25, 2019

A Feasibility Study to Evaluate Skin Cleansing With a Sodium Hypochlorite Wash

An interventional study of Sodium Hypochlorite Cleanser in Arterial Bypass Graft Surgery, sponsored by TopMD Skin Care, Inc.. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-25.

Sponsored by TopMD Skin Care, Inc. · Not applicable, Interventional, and Supportive care

Why this study was withdrawn
Enrollment difficulty
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Feasibility study in approximately 20 subjects to investigate the rate of infection with subjects undergoing elective lower extremity arterial bypass graft surgery or femoral endarterectomy. The subjects are instructed to shower with the sodium hypochlorite body wash daily, or as modified by the physician, for 5 of the 7 days leading to their surgery.

Read the detailed description

This is a feasibility study in approximately 20 subjects over a 5-week period per subject. The study will investigate the rate of infection with subjects undergoing elective lower extremity arterial bypass graft surgery or femoral endarterectomy. The subjects are instructed to shower with the sodium hypochlorite body wash daily, or as modified by the physician, for 5 of the 7 days leading to their surgery.

02

Conditions studied

  • Arterial Bypass Graft Surgery
03

In context

Lead sponsor

TopMD Skin Care, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Subject is male or female greater than the age of 18 years.
  2. Subject is willing and able to give written informed consent and to comply with the requirements of the study.
  3. Subject has 5 or more days of time prior to elective surgery scheduled to sign consent and begin washing parameters.
  4. Subject is capable of taking a shower and lathering their entire body, or is able to be helped by a caregiver to shower each day with lather on their entire body for 5 out of 7 days immediately prior to elective surgery. (Modifications for bath usage can be made by the physician if the result of the product being left on the skin of the entire body for the time commitment is maintained, and if the body can be rinsed with poured water. Bed bath is not considered an allowable modification.)

Exclusion criteria

Exclusion Criteria:

    1. Subject is on antibiotics prior to surgery.

      1. Subject is unable to maintain washing regimen for the full study term.
      1. Subject is unable to follow pre-surgery cleansing instructions for 5 of the 7 days immediately prior to surgery. (Bed bath is not considered a cleansing day.)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Other
    Prospective Subjects

    Other: Sodium Hypochlorite Cleanser

Interventions

  • OtherSodium Hypochlorite Cleanser

    Cleansing with CLn BodyWash

06

What researchers measure

Primary outcomes

  1. Decrease in percentage

    Fewer infected patients than in the retrospective data

    Time frame: 5 week per subject

07

Study locations

1 site
  • Texas Vascular Associates, PA
    Dallas, Texas 75226, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03534388
Lead sponsor
TopMD Skin Care, Inc.
Responsible party
Sponsor
First posted
May 23, 2018
Start date
May 10, 2018
Primary completion
Jul 1, 2019 (estimated)
Completion
Dec 1, 2019 (estimated)
Last update
Sep 25, 2019

Study contacts

Stephen E Hohmann, MD
principal investigator · Texas Vascular Associates

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion